Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18547364 | 0.85 | JAK2 (0.44) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547002 | 0.82 | P2RX3 (0.45) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547130 | 0.82 | KCNH2 (0.40) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547185 | 0.82 | CNR2 (0.46) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18562613 | 0.81 | P2RX3 (0.40) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547456 | 0.81 | NPC1 (0.44) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547103 | 0.80 | NPC1 (0.40) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547105 | 0.80 | NPC1 (0.40) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547191 | 0.80 | NPC1 (0.40) | LMNASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL18547398 | 0.80 | CNR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | LMNA 3811/4885SMN1; SMN2 1950/4885MAPT 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.